CPChitta Ranjan Patra

Chitta Ranjan Patra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chitta Ranjan Patra has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Debabrata Mukhopadhyay

    Department of Biochemistry and Molecular Biology, and Mayo Clinic College of Medicine and Sciences, Jacksonville, USA

    3 shared publications
  • Resham Bhattacharya

    10 Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States of America

    3 shared publications
  • Debabrata Mukhopadhyay

    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, USA

    2 shared publications
  • Priyabrata Mukherjee

    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, USA

    2 shared publications
  • Priyabrata Mukherjee

    Department of Biochemistry and Molecular Biology

    2 shared publications
  • Aharon Gedanken

    Department of Chemistry and Kanbar Laboratory for Nanomaterials, Bar-Ilan University Center for Advanced Materials and Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel

    1 shared publication

Latest Publications

  • Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide

    by Amitava Das, Priyabrata Mukherjee, Sumit K Singla, Praveen Guturu, Megan C Frost, Debabrata Mukhopadhyay, Vijay H Shah, Chitta Ranjan Patra

    Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV–visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 °C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.


  • In vivo toxicity studies of europium hydroxide nanorods in mice

    by Chitta Ranjan Patra, Soha S. Abdel Moneim, Enfeng Wang, Shamit Dutta, Sujata Patra, Michal Eshed, Priyabrata Mukherjee, Aharon Gedanken, Vijay H. Shah, Debabrata Mukhopadhyay


  • Open Access

    The neurotransmitter dopamine modulates vascular permeability in the endothelium

    by Resham Bhattacharya, Sutapa Sinha, Su-Ping Yang, Chittaranjan Patra, Shamit Dutta, Enfeng Wang, Debabrata Mukhopadhyay

    Vascular permeability factor/Vascular endothelial growth factor (VPF/VEGF), a multifunctional cytokine, is a potent inducer of vascular permeability, an important early step in angiogenesis. It is known that the neurotransmitter dopamine can inhibit VPF/VEGF mediated angiogenesis, in particular microvascular permeability, but the effectors of this action remain unclear.


  • Open Access

    Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis

    by Priyabrata Mukherjee, Resham Bhattacharya, Nancy Bone, Yean K Lee, Chitta R Patra, Shanfeng Wang, Lichun Lu, Charla Secreto, Pataki C Banerjee, Michael J Yaszemski, et al.

    B-Chronic Lymphocytic Leukemia (CLL) is an incurable disease predominantly characterized by apoptosis resistance. We have previously described a VEGF signaling pathway that generates apoptosis resistance in CLL B cells. We found induction of significantly more apoptosis in CLL B cells by co-culture with an anti-VEGF antibody. To increase the efficacy of these agents in CLL therapy we have focused on the use of gold nanoparticles (GNP). Gold nanoparticles were chosen based on their biocompatibility, very high surface area, ease of characterization and surface functionalization. We attached VEGF antibody (AbVF) to the gold nanoparticles and determined their ability to kill CLL B cells. Gold nanoparticles and their nanoconjugates were characterized using UV-Visible spectroscopy (UV-Vis), transmission electron microscopy (TEM), thermogravimetric analysis (TGA) and X-ray photoelectron spectroscopy (XPS). All the patient samples studied (N = 7) responded to the gold-AbVF treatment with a dose dependent apoptosis of CLL B cells. The induction of apoptosis with gold-AbVF was significantly higher than the CLL cells exposed to only AbVF or GNP. The gold-AbVF treated cells showed significant down regulation of anti-apoptotic proteins and exhibited PARP cleavage. Gold-AbVF treated and GNP treated cells showed internalization of the nanoparticles in early and late endosomes and in multivesicular bodies. Non-coated gold nanoparticles alone were able to induce some levels of apoptosis in CLL B cells. This paper opens up new opportunities in the treatment of CLL-B using gold nanoparticles and integrates nanoscience with therapy in CLL. In future, potential opportunities exist to harness the optoelectronic properties of gold nanoparticles in the treatment of CLL.


  • Open Access

    Inorganic phosphate nanorods are a novel fluorescent label in cell biology

    by Chitta Ranjan Patra, Resham Bhattacharya, Sujata Patra, Sujit Basu, Priyabrata Mukherjee, Debabrata Mukhopadhyay

    We report the first use of inorganic fluorescent lanthanide (europium and terbium) ortho phosphate [LnPO4·H2O, Ln = Eu and Tb] nanorods as a novel fluorescent label in cell biology. These nanorods, synthesized by the microwave technique, retain their fluorescent properties after internalization into human umbilical vein endothelial cells (HUVEC), 786-O cells, or renal carcinoma cells (RCC). The cellular internalization of these nanorods and their fluorescence properties were characterized by fluorescence spectroscopy (FS), differential interference contrast (DIC) microscopy, confocal microscopy, and transmission electron microscopy (TEM). At concentrations up to 50 μg/ml, the use of [3H]-thymidine incorporation assays, apoptosis assays (TUNEL), and trypan blue exclusion illustrated the non-toxic nature of these nanorods, a major advantage over traditional organic dyes